Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health problem closely linked to dietary habits, particularly high fructose consumption. This study investigates the combined effects of fructose and common food preservatives (sodium benzoate, sodium nitrite, and potassium sorbate) on the development and progression of MASLD. Methods: We utilized a human microbiota-associated mouse model, administering 10% fructose with or without preservatives for 11 weeks. Liver histology, hepatic gene expression (microarray analysis), biochemical markers, cytokine profiles, intestinal permeability, and gut microbiome composition (16S rRNA and Internal Transcribed Spacer (ITS) sequencing) were evaluated. Results: Fructose and potassium sorbate synergistically induced liver pathology characterized by increased steatosis, inflammation and fibrosis. These histological changes were associated with elevated liver function markers and altered lipid profiles. The treatments also induced significant changes in both the bacterial and fungal communities and disrupted intestinal barrier function, leading to increased pro-inflammatory responses in the mesenteric lymph nodes. Liver gene expression analysis revealed a wide range of transcriptional changes induced by fructose and modulated by the preservative. Key genes involved in lipid metabolism, oxidative stress, and inflammatory responses were affected. Conclusions: Our findings highlight the complex interactions between dietary components, gut microbiota, and host metabolism in the development of MASLD. The study identifies potential risks associated with the combined consumption of fructose and preservatives, particularly potassium sorbate. Our data reveal new mechanisms that are involved in the development of MASLD and open up a new avenue for the prevention and treatment of MASLD through dietary interventions and the modulation of the microbiome.

Laboratory of Gnotobiology Institute of Microbiology Czech Academy of Sciences 549 22 Novy Hradek Czech Republic

Zobrazit více v PubMed

Eslam M., Sanyal A.J., George J. International Consensus Panel MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158:1999–2014. doi: 10.1053/j.gastro.2019.11.312. PubMed DOI

Younossi Z.M., Golabi P., Paik J.M., Henry A., Van Dongen C., Henry L. The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Hepatology. 2023;77:1335–1347. doi: 10.1097/HEP.0000000000000004. PubMed DOI PMC

Rinella M.E. Nonalcoholic Fatty Liver Disease: A Systematic Review. JAMA. 2015;313:2263–2273. doi: 10.1001/jama.2015.5370. PubMed DOI

Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Järvinen H., Svegliati-Baroni G. From the Metabolic Syndrome to NAFLD or Vice Versa? Dig. Liver Dis. 2010;42:320–330. doi: 10.1016/j.dld.2010.01.016. PubMed DOI

Hrncir T., Hrncirova L., Kverka M., Hromadka R., Machova V., Trckova E., Kostovcikova K., Kralickova P., Krejsek J., Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms. 2021;9:957. doi: 10.3390/microorganisms9050957. PubMed DOI PMC

Betrapally N.S., Gillevet P.M., Bajaj J.S. Gut Microbiome and Liver Disease. Transl. Res. 2017;179:49–59. doi: 10.1016/j.trsl.2016.07.005. PubMed DOI PMC

Shen F., Zheng R.-D., Sun X.-Q., Ding W.-J., Wang X.-Y., Fan J.-G. Gut Microbiota Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease. Hepatobiliary Pancreat. Dis. Int. 2017;16:375–381. doi: 10.1016/S1499-3872(17)60019-5. PubMed DOI

Aron-Wisnewsky J., Vigliotti C., Witjes J., Le P., Holleboom A.G., Verheij J., Nieuwdorp M., Clément K. Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders. Nat. Rev. Gastroenterol. Hepatol. 2020;17:279–297. doi: 10.1038/s41575-020-0269-9. PubMed DOI

Hrncir T. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms. 2022;10:578. doi: 10.3390/microorganisms10030578. PubMed DOI PMC

Zhang H., Lu Y., Zhang Y., Dong J., Jiang S., Tang Y. DHA-Enriched Phosphatidylserine Ameliorates Cyclophosphamide-Induced Liver Injury via Regulating the Gut-Liver Axis. Int. Immunopharmacol. 2024;140:112895. doi: 10.1016/j.intimp.2024.112895. PubMed DOI

Jensen T., Abdelmalek M.F., Sullivan S., Nadeau K.J., Green M., Roncal C., Nakagawa T., Kuwabara M., Sato Y., Kang D.-H., et al. Fructose and Sugar: A Major Mediator of Non-Alcoholic Fatty Liver Disease. J. Hepatol. 2018;68:1063–1075. doi: 10.1016/j.jhep.2018.01.019. PubMed DOI PMC

Hrncirova; Machova; Trckova; Krejsek; Hrncir Food Preservatives Induce Proteobacteria Dysbiosis in Human-Microbiota Associated Nod2-Deficient Mice. Microorganisms. 2019;7:383. doi: 10.3390/microorganisms7100383. PubMed DOI PMC

Hrncirova L., Hudcovic T., Sukova E., Machova V., Trckova E., Krejsek J., Hrncir T. Human Gut Microbes Are Susceptible to Antimicrobial Food Additives in Vitro. Folia Microbiol. 2019;64:497–508. doi: 10.1007/s12223-018-00674-z. PubMed DOI

Chassaing B., Koren O., Goodrich J.K., Poole A.C., Srinivasan S., Ley R.E., Gewirtz A.T. Dietary Emulsifiers Impact the Mouse Gut Microbiota Promoting Colitis and Metabolic Syndrome. Nature. 2015;519:92–96. doi: 10.1038/nature14232. PubMed DOI PMC

Lebeaupin C., Proics E., de Bieville C.H.D., Rousseau D., Bonnafous S., Patouraux S., Adam G., Lavallard V.J., Rovere C., Le Thuc O., et al. ER Stress Induces NLRP3 Inflammasome Activation and Hepatocyte Death. Cell Death Dis. 2015;6:e1879. doi: 10.1038/cddis.2015.248. PubMed DOI PMC

Chu H., Duan Y., Yang L., Schnabl B. Small Metabolites, Possible Big Changes: A Microbiota-Centered View of Non-Alcoholic Fatty Liver Disease. Gut. 2019;68:359–370. doi: 10.1136/gutjnl-2018-316307. PubMed DOI

Bolyen E., Rideout J.R., Dillon M.R., Bokulich N.A., Abnet C.C., Al-Ghalith G.A., Alexander H., Alm E.J., Arumugam M., Asnicar F., et al. Reproducible, Interactive, Scalable and Extensible Microbiome Data Science Using QIIME 2. Nat. Biotechnol. 2019;37:852–857. doi: 10.1038/s41587-019-0209-9. PubMed DOI PMC

Andrews S. FastQC: A Quality Control Tool for High Throughput Sequence Data. [(accessed on 5 September 2024)]. Available online: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/

Martin M. Cutadapt Removes Adapter Sequences from High-Throughput Sequencing Reads. EMBnet. J. 2011;17:10–12. doi: 10.14806/ej.17.1.200. DOI

Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J.A., Holmes S.P. DADA2: High-Resolution Sample Inference from Illumina Amplicon Data. Nat. Methods. 2016;13:581–583. doi: 10.1038/nmeth.3869. PubMed DOI PMC

Katoh K. MAFFT: A Novel Method for Rapid Multiple Sequence Alignment Based on Fast Fourier Transform. Nucleic Acids Res. 2002;30:3059–3066. doi: 10.1093/nar/gkf436. PubMed DOI PMC

Price M.N., Dehal P.S., Arkin A.P. FastTree: Computing Large Minimum Evolution Trees with Profiles Instead of a Distance Matrix. Mol. Biol. Evol. 2009;26:1641–1650. doi: 10.1093/molbev/msp077. PubMed DOI PMC

Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glöckner F.O. The SILVA Ribosomal RNA Gene Database Project: Improved Data Processing and Web-Based Tools. Nucleic Acids Res. 2013;41:D590–D596. doi: 10.1093/nar/gks1219. PubMed DOI PMC

Lin H., Peddada S.D. Analysis of Compositions of Microbiomes with Bias Correction. Nat. Commun. 2020;11:3514. doi: 10.1038/s41467-020-17041-7. PubMed DOI PMC

R Core Team . R: A Language and Environment for Statistical Computing. R Core Team; Vienna, Austria: 2021.

RStudio Team . RStudio: Integrated Development Environment for R. RStudio Team; Boston, MA, USA: 2021.

Wang H., Guo Y., Han W., Liang M., Xiao X., Jiang X., Yu W. Tauroursodeoxycholic Acid Improves Nonalcoholic Fatty Liver Disease by Regulating Gut Microbiota and Bile Acid Metabolism. J. Agric. Food Chem. 2024;72:20194–20210. doi: 10.1021/acs.jafc.4c04630. PubMed DOI

Lang S., Duan Y., Liu J., Torralba M.G., Kuelbs C., Ventura-Cots M., Abraldes J.G., Bosques-Padilla F., Verna E.C., Brown R.S., et al. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology. 2020;71:522–538. doi: 10.1002/hep.30832. PubMed DOI PMC

Sokol H., Leducq V., Aschard H., Pham H.-P., Jegou S., Landman C., Cohen D., Liguori G., Bourrier A., Nion-Larmurier I., et al. Fungal Microbiota Dysbiosis in IBD. Gut. 2017;66:1039–1048. doi: 10.1136/gutjnl-2015-310746. PubMed DOI PMC

Depommier C., Everard A., Druart C., Plovier H., Van Hul M., Vieira-Silva S., Falony G., Raes J., Maiter D., Delzenne N.M., et al. Supplementation with Akkermansia Muciniphila in Overweight and Obese Human Volunteers: A Proof-of-Concept Exploratory Study. Nat. Med. 2019;25:1096–1103. doi: 10.1038/s41591-019-0495-2. PubMed DOI PMC

Demir M., Lang S., Hartmann P., Duan Y., Martin A., Miyamoto Y., Bondareva M., Zhang X., Wang Y., Kasper P., et al. The Fecal Mycobiome in Non-Alcoholic Fatty Liver Disease. J. Hepatol. 2022;76:788–799. doi: 10.1016/j.jhep.2021.11.029. PubMed DOI PMC

Fotis D., Liu J., Dalamaga M. Could Gut Mycobiome Play a Role in NAFLD Pathogenesis? Insights and Therapeutic Perspectives. Metab. Open. 2022;14:100178. doi: 10.1016/j.metop.2022.100178. PubMed DOI PMC

Mouries J., Brescia P., Silvestri A., Spadoni I., Sorribas M., Wiest R., Mileti E., Galbiati M., Invernizzi P., Adorini L., et al. Microbiota-Driven Gut Vascular Barrier Disruption Is a Prerequisite for Non-Alcoholic Steatohepatitis Development. J. Hepatol. 2019;71:1216–1228. doi: 10.1016/j.jhep.2019.08.005. PubMed DOI PMC

Tilg H., Adolph T.E., Moschen A.R. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833–842. doi: 10.1002/hep.31518. PubMed DOI PMC

Softic S., Stanhope K.L., Boucher J., Divanovic S., Lanaspa M.A., Johnson R.J., Kahn C.R. Fructose and Hepatic Insulin Resistance. Crit. Rev. Clin. Lab. Sci. 2020;57:308–322. doi: 10.1080/10408363.2019.1711360. PubMed DOI PMC

Semmler G., Datz C., Trauner M. Eating, Diet, and Nutrition for the Treatment of Non-Alcoholic Fatty Liver Disease. Clin. Mol. Hepatol. 2022;29:S244–S260. doi: 10.3350/cmh.2022.0364. PubMed DOI PMC

Abdelmalek M.F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R.J., Diehl A.M., Nonalcoholic Steatohepatitis Clinical Research Network Increased Fructose Consumption Is Associated with Fibrosis Severity in Patients with Nonalcoholic Fatty Liver Disease. Hepatology. 2010;51:1961–1971. doi: 10.1002/hep.23535. PubMed DOI PMC

Chassaing B., Van De Wiele T., De Bodt J., Marzorati M., Gewirtz A.T. Dietary Emulsifiers Directly Alter Human Microbiota Composition and Gene Expression Ex Vivo Potentiating Intestinal Inflammation. Gut. 2017;66:1414–1427. doi: 10.1136/gutjnl-2016-313099. PubMed DOI PMC